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Abstract In 2004, the Surviving Sepsis Campaign was
launched to increase awareness and improve the outcome of
severe sepsis. Accordingly, in Jönköping County, Sweden, a
strong recommendation to perform a blood culture before the
start of intravenous antibiotic treatment was introduced in
2007. Moreover, a reminder was included in the laboratory
report to consult an infectious disease specialist when Staph-
ylococcus aureus was isolated from a blood culture. Retro-
spectively, patients with at least one blood culture growing S.
aureus during 2002 through 2003 (pre intervention n =58) or
during 2008 through 2009 (post intervention n =100) were
included. Medical records were evaluated regarding clinical
data and outcome. Blood culture isolates were characterized
by antibiotic susceptibility testing (AST) and S. aureus pro-
tein A (spa ) gene typing. The annual incidence of S. aureus
bacteremia (SAB) increased from 28 per 100,000 inhabitants
at the pre intervention period to 45 per 100,000 at the post
intervention period (p =0.046). During post intervention, the
SAB incidence was significantly higher in men (p =0.009).
The mortality rate during hospital stay was 14 % during pre
intervention and 18 % during post intervention (p =0.47). The
most common spa types were t012 and t084. The Surviving
Sepsis Campaign resulted in an increased number of detected
cases of SAB. Themortality rate was the same before and after
the intervention, and no spa type correlated to certain clinical
manifestations or mortality.
Background
Staphylococcus aureus bacteremia (SAB) correlates to sepsis,
severe sepsis, and septic shock with high mortality [1]. An
early diagnosis and a structured management and treatment of
patients with SAB are essential to prevent a fatal progress [2,
3]. Guidelines for the management of severe sepsis and septic
shock were introduced in 2004 [4]. The rate of methicillin-
resistant S. aureus (MRSA) in Sweden is low [5]; however,
knowledge of the local prevalence of MRSA is crucial in the
choice of empirical treatment [6].
In Jönköping County in the southern part of Sweden, a
patient safety project aiming at the early identification and
treatment of patients with suspected severe sepsis was intro-
duced in 2007, in accordance with Dellinger et al. [4]. This
included a strong recommendation to perform a blood culture
before the start of an intravenous antibiotic treatment and a
reminder in the laboratory report to consult an infectious disease
specialist when S. aureus was isolated from a blood culture.
In this study, we investigate the incidence and outcome of
SAB in Jönköping, Sweden, 2002 through 2003 and 2008
through 2009 to evaluate if the patient safety project resulted
in an increase in SAB cases detected. Furthermore, we inves-
tigate the molecular epidemiology of S. aureus based on
sequencing of the repeat region of the S. aureus protein A
gene (spa typing) [7].
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The study was performed at the County Hospital Ryhov in
Jönköping, situated in the southern part of Sweden. The
hospital has 638 beds and 3,500 employees. Inhabitants of
the catchment area with an age above 18 years averaged 105,
300 in the pre intervention period and 112,900 in the post
intervention period.
Study design
This retrospective study is based on the evaluation of medical
records from all patients (n =158) with SAB at a pre interven-
tion period of 2 years (2002 and 2003) (n =58) and a post
intervention period of 2 years (2008 and 2009) (n =100)
comparing medical history, clinical findings, and laboratory
results. No independent evaluation of the clinical diagnosis
was performed. For epidemiological purposes, spa typing of
S. aureus in blood culture isolates was performed. In total,
163 S. aureus isolates from 148 different patients were avail-
able for spa typing. To evaluate the long-term effect of the
intervention, figures (number of blood cultures, number of
patients with SAB, and annual incidence) from the 2 years
2011 and 2012 were included as a follow up.
Intervention
In 2004, new guidelines, aiming at an increased attention to
patients at risk for severe sepsis, were introduced. The guide-
lines included a strong recommendation to always perform a
blood culture before administrating the first intravenous anti-
biotic dose and a reminder in the laboratory report to consult
an infectious disease specialist when S. aureus was isolated
from a blood culture. This was implemented in Jönköping
between 2003 and 2008, and, noteworthy, the nurse was
committed to be responsible for taking a blood culture before
starting the antibiotic treatment.
Definitions
SABwas defined as S. aureus obtained from one or both blood
culture bottles. Severe sepsis was defined according to the
American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference Committee [8]. Nosocomial
infections were defined as a positive blood culture taken later
than 48 h after arrival to the hospital. The mortality was the all-
cause mortality. Recurrence was defined as a new episode of
SAB within 1 year, but more than 4 weeks after the time of the
first diagnosis. A relapse was defined as a recurrence caused by
the same spa type as the primary episode and a reinfection was
defined as a recurrence with a different spa type.
Antibiotic susceptibility testing
Antibiotic susceptibility testing (AST) was performed by the
disk diffusion method on Iso-Sensitest Agar (Oxoid, Ltd.,
Basingstoke, UK) using specific antibiotic disks (Oxoid,
Ltd., Basingstoke, UK) pre and post intervention according
to the Swedish standard for AST (http://www.srga.org). The
recommendations and antimicrobial susceptibility testing
criteria of the Swedish Reference Group of Antibiotics
(SRGA) were adhered to. The SRGA has, since 2002, adopted
all recommendations on breakpoints and methodology from
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST).
spa typing
The spa typing of blood culture isolates (stored in skimmed
milk at −80 °C) was performed as previously described [7, 9].
Sequencing was performed byGATCBiotech (GATCBiotech
AG, Konstanz, Germany) and each isolate was assigned an
spa type using the Ridom StaphType software (v1.5.21,
Ridom GmbH, Würzburg, Germany). The Ridom StaphType
software was also used to obtain based upon repeat pattern
(BURP) clusters [10], enabling the determination of clonal
relatedness. The default parameters (x =5; y =4) were applied.
Panton–Valentine leukocidin testing
Panton–Valentine leukocidin (PVL) testing was performed on
blood culture isolates from patients with pneumonia, accord-
ing to Lina et al. [11].
Statistical analyses
IBMSPSS Statistics 19 andMicrosoft Excel 2007were used. A
two-sided Chi-square test with one degree of freedomwas used
for the evaluation of proportions and the Mann–Whitney test
was used for calculations of differences between means. A
p-value ≤0.05 was considered significant. Antibiotic-sensitive
and -intermediate isolates were combined in statistical analyses.
Ethical considerations
This study complied with current Swedish laws.
Results
The number of blood cultures increased from 8,616 at pre
intervention to 14,842 at post intervention (72 %, p <0.0001).
The number of patients suffering from SAB during the pre
intervention period was 58 and at post intervention it was 100
(73 %, p =0.0037). The proportion of patients with SAB was
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the same during the pre and post intervention periods. The
annual incidence of SAB increased from 28 per 100,000
inhabitants at pre intervention to 45 per 100,000 at post
intervention (p =0.046) (Table 1). At pre intervention, no
statistically significant difference (p =0.071) in the SAB rate
was seen between women and men, whereas at post interven-
tion, the SAB rate was significantly higher in men (p =0.009).
The number of blood cultures performed was significantly
higher for men compared to women at pre (p <0.0001) and
post (p <0.0001) intervention (Table 1), and the increase of
performed blood cultures was higher for men than for
women (p <0.0001).
The median age at SAB diagnosis was 69 and 75 years for
men (p =0.11) and 74 and 74 years for women (p =0.33)
during pre and post intervention, respectively. For men, the
age-specific SAB rates were highest at 50–59 years of age at
pre intervention and 80–89 years at post intervention. For
women, the corresponding figures were 70–79 years at pre
intervention and 50–59 years at post intervention (Fig. 1). At
follow up, a further increase (p <0.0001) in the number (17,
783) of blood cultures performed was noted, as well as a
sustained rate (p =0.35) of patients with SAB (n =115) and
annual incidence of 44 per 100,000 (p =0.92).
The mortality among SAB patients during hospital stay
was 14 and 18 % at pre and post intervention, respectively.
The 12 months mortality was 50 and 44 % at pre and post
intervention, respectively (Table 2). There was no difference
in the mortality between men and women.
Endocarditis, spondylitis, and pneumonia were the most
common manifestations related to SAB. During the pre inter-
vention period, none of the seven patients with endocarditis
was sent to cardiac surgery during hospital stay; however, four
out of nine patients were sent to cardiac surgery at post
intervention. Amajor part of patients with SAB had an unclear
focus (Table 2).
The number of patients suffering from a nosocomial dis-
ease was 12 (21 %) at pre intervention and 24 (24 %) at post
intervention (p =0.63). The time from arrival at the hospital to
the first antibiotic dosage administered (not including
nosocomial disease) was, on average, 14 h (median 6 h) at
pre intervention and 11 h (median 4 h) at post intervention
(p =0.38). The mean duration of intravenous antibiotic treat-
ment was 13 days at pre intervention and 15.5 days at post
intervention (p =0.23). Cefuroxime was the most common
antibiotic drug at the start of treatment pre intervention, given
to 45 (78 %) patients, and cefotaxime at post intervention,
given to 25 patients (25 %). Cloxacillin was given to 79
patients (50 %) during treatment, but was used as the first
antibiotic in only 12 cases (8 %). Oral antibiotics after a
period of intravenous antibiotics were given to 48 pa-
tients (83 %) pre intervention and to 67 patients (67 %)
post intervention (p =0.03).
At pre intervention, 45 out of 58 patients (78 %) and at post
intervention, 69 out of 100 patients (69 %) were referred to a
specialist in infectious diseases (p =0.25), and 19 (33 %) and
26 (26 %) at pre and post intervention, respectively, were
treated at the infectious disease department (p =0.36). Hospi-
talization was delayed (median 1 day) for 28 and 39 %
(p =0.15) of patients at pre and post intervention, respectively.
The mortality rate of these patients did not differ from the
mortality of patients immediately hospitalized at the first
medical contact (p =0.35). The number of SAB patients treat-
ed at the intensive care unit increased from four (7 %) patients
Table 1 Annual incidence of
Staphylococcus aureus bacter-
emia (SAB)
a Significant if p-value≤0.05
bDifference between pre and post
intervention
c Compares the years 2002–2003
with 2008–2009
d Compares men and women for
each period of time
2002–2003 p-Valuea 2008–2009 p-Valuea %b
Blood cultures 8,616 14,842 <0.0001c +72
Men 4,538 8,224 +81
Women 4,078 <0.0001d 6,618 <0.0001d +62
Number of positive blood
cultures with S. aureus
161 218 0.019c +35
SAB 58 100 0.0037c +72
Men 35 62 +77
Women 23 0.071d 38 0.009d +65
Annual incidence per 100,000 28 45 0.046c +61
Fig. 1 Age-specific rates of cases with Staphylococcus aureus bacter-
emia (SAB) during the years 2002–2003 and 2008–2009
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pre intervention to 22 (22 %) patients post intervention
(p =0.02). Heart ultrasound examination was performed on
30 patients at pre intervention (52 %) and on 76 patients at
post intervention (76 %) (p =0.0017). The average length of
hospital stay was 20 days at pre intervention and 24 days at
post intervention (p =0.81).
spa typing
In total, 163 out of 173 isolates were available for spa typing
from 148 of the 158 patients. During pre and post intervention,
42 and 58 different spa types were detected, respectively. The
BURP cluster analysis resulted in three dominating spa clonal
complexes (CCs) (Fig. 2). These comprised 55 and 61% of all
spa types at pre and post intervention, respectively. The three
clusters were equally distributed within each time period and
between the two periods. Minor differences in the spa
type distribution between pre and post intervention were
noted (Fig. 2).
A total of 12 patients suffered from 13 recurrences. All
isolates were available for spa typing from both the primary
infection and the recurrence. Eleven patients had relapses and
two patients had a reinfection. The spa types seen in the
reinfected patients were t9201/t246 and t183/t505, respective-
ly. Two patients had a dual infection, i.e., S. aureus of
different spa types isolated from the same bottle. These
spa types were t021/t037 (resistant to fusidic acid) and
t084/t362, respectively. No spa type was associated
with increased risk of death or clinical manifestations
(Table 2).
AST
All of the 171 out of 173 S. aureus isolates analyzed were
sensitive to clindamycin, tobramycin, trimethoprim–sulfa-
methoxazole, vancomycin, erythromycin, rifampicin,
netilmicin, linezolid, quinolones meropenem, cefadroxil, and
cefuroxime. Fusidic acid AST resulted in 14 resistant isolates
pre intervention compared to one resistant isolate post inter-
vention. No MRSA isolates were detected.
PVL testing
No PVL-positive isolates were found.
Discussion
The main finding of this study is that the implementation of a
quality improvement program, aiming at the early detection of
patients with severe sepsis, resulted in a 61 % increase in the
annual incidence of SAB, which was sustained at the 3 years
follow up. This indicates that a substantial number of SABs
remained undetected before the intervention. The greatest
increase in SAB was seen in men, resulting in a significantly
higher SAB rate in men than in women at post intervention,
which is in agreement with other reports [12, 13]. Further-
more, no spa types correlated to increased risk of death or
specific clinical manifestations.
Our pre intervention SAB incidence figures are in line with
the results of Jacobsson et al. [14] performed in geographic
Table 2 All-cause mortality after
Staphylococcus aureus bacter-
emia (SAB) and clinical manifes-
tations at pre and post
intervention
a Significant if p-value≤0.05
bManifestations may occur more
than once in an individual
Years 2002–2003 (%) p-Valuea Years 2008–2009 (%) p-Valuea
Men Women Men Women
Mortality
During hospital stay 6 (17.1) 2 (8.7) 0.36 11 (17.7) 7 (18.4) 0.93
Within 3 months
after discharge
5 (14.3) 4 (17.4) 0.75 8 (12.9) 4 (10.5) 0.72
During 3–12 months
after discharge
9 (25.7) 3 (13.0) 0.24 11 (17.7) 3 (7.9) 0.17
Total 20 (57.1) 9 (39.1) 0.18 30 (48.3) 14 (36.8) 0.25
Clinical manifestationsb Total Total
Skin or soft tissue injury 8 (14) 29 (29) 0.03
Endocarditis 7 (12) 9 (9) 0.54
Spondylitis 4 (7) 11 (11) 0.4
Osteitis 4 (7) 6 (6) 0.82
Arthritis 3 (5) 7 (6) 0.65
Prosthetic infection 1 (2) 2 (2) 0.90
Pneumonia 1 (2) 16 (16) 0.0052
Unclear focus 23 (40) 25 (25) 0.054
792 Eur J Clin Microbiol Infect Dis (2014) 33:789–795
proximity and in a multinational study [5], whereas our post
intervention figures are significantly higher. Both studies in-
cluded, in contrast to our study, patients below 18 years of age.
The retrospective design of our study may have underestimated
the true incidence [15]; however, our increased sampling may
have compensated for this and, thus, better reflects the true SAB
incidence in the population.
The mortality rates during hospital stay and after 12 months
did not change significantly between pre and post intervention.
Hence, the SAB patients detected through the quality
Table 3 The most common isolates from other studies in comparison with the 14 most common spa types in this study
spa types This study, n =163 Aamot et al. [18], n =353 Sangvik et al. [26], n =1,113 Matussek et al. [19], n =160 Mernelius et al. [20], n =1,635
No.(%) of isolates No. (%) of isolates No. (%) of isolates No.(%) of isolates No. (%) of isolates
t012 13 (8.0 %) 14 (4.0 %) 94 (8.4 %) 20 (12.5 %) 65 (4.0 %)
t084 11 (6.7 %) 46 (13.0 %) 84 (7.6 %) 104 (6.4 %)
t246 8 (4.9 %)
t021 7 (4.3 %) 42 (3.8 %) 10 (6.25 %) 42 (2.6 %)
t050 7 (4.3 %)
t015 7 (4.3 %) 38 (3.4 %) 10 (6.25 %) 50 (3.1 %)
t230 6 (3.7 %)
t091 4 (2.5 %)
t505 4 (2.5 %)
t065 3 (1.8 %) 15 (4.2 %) 55 (4.9 %)
t026 3 (1.8 %)
t1711 3 (1.8 %)
t002 3 (1.8 %) 18 (5.1 %) 30 (2.7 %) 41 (2.5 %)
t005 3 (1.8 %)
Years 2002-2003 Years 2008-2009 
spa-CC 021 (n=13) no founder (n=5) spa-CC 021/012 (n=20) spa-CC 005 (n=5) no founder (n=3)
spa-CC 015 (n=10) spa-CC 050/015 (n=22) no founder (n=2) no founder (n=3)
spa-CC 084 (n=10) spa-CC 084 (n=19) no founder (n=8) no founder (n=2)
Singletons: t002, t005, t078, t127, t164, t183, t185, t186, t246, Singletons: t082, t127, t230, t252, t362, t252, t688, t793, t2078, t2313, t2451
t267, t358, t493, t888, t4407 Excluded spa types: t026, t362, t693, t1209, t2453
Excluded spa types: t026, t287 spa types without alignments: t9204, t9207
spa types without alignments: t6406, t9201
Fig. 2 Based upon repeat pattern (BURP) clustering of 60 isolates from
years 2002–2003 and 103 isolates from years 2008–2009 based on spa
types. The spa type with the highest founder score is defined as the
founder of the cluster and is given the cluster its name. Subfounders are
the spa types with the second highest founder score. Founders and
subfounders are marked in gray. Each dot in a cluster represents a unique
spa type and the diameter of the dot represents the quantity of the spa
type
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improvement program seems to have comparable mortality as
the pre intervention patients. In contrast to a recent report by
Jacobson and Nasic showing increased mortality in women, we
show similar mortality rates between men and women [16].
The numbers of clinical manifestations are too few to draw
significant conclusions. However, one serious and common
manifestation was infective endocarditis [17], seen in approxi-
mately 10 % of the patients in this study. Notably, although we
observed an increase in transesophageal or transthoracic echo-
cardiography between pre and post intervention, the rate of
endocarditis remained stable. None of the patients with endo-
carditis were sent to cardiac surgery during pre intervention
compared to four out of nine patients during post intervention,
which may reflect modified treatment recommendations.
Among the other clinical manifestations, pneumonias
and skin and soft tissue infections were higher at post
intervention. Only the isolates from the patients suffer-
ing from pneumonia were PVL tested and none were
positive. The relatively high proportion of pneumonias
should, therefore, be interpreted with caution, since the
study was performed retrospectively without an indepen-
dent evaluation of the clinical diagnosis.
Between pre and post intervention, we found an average
non-significant decrease of 3 h from admission to hospital to
the start of antibiotic treatment and longer duration of intra-
venous treatment with antibiotics.
Although the intervention program included a recommen-
dation to contact an infectious disease specialist, no increase
in referrals was noted. Moreover, delay to hospitalization was
not decreased.
We found a large diversity of spa types and stability over
time for common types, which confirm recent Norwegian
findings [18]. The common spa types were also found in
recent reports on healthy individuals from the same geograph-
ic area [19–21], as in our study (Table 3). This is in agreement
with the finding that a successful colonizing strain can trans-
form into a life-threatening human pathogen at any time
[22–24]. Notably, spa type t084, frequently found during both
pre and post intervention, could not be detected in the study by
Matussek et al. [19] performed during the time for our pre
intervention, but was later detected in healthy individuals [20].
This may indicate that this type was first established in clinical
infections in our region. No specific spa type correlated to
clinical manifestations or mortality, although a correlation to
mortality was recently reported [18].
Relapse was more common than reinfection, and the two
patients with reinfection had spa types of great difference.
The two patients with dual infection, in contrast, had two
closely related spa types, which may indicate genetic changes
during infection.
A generally low rate of antibiotic resistance was observed
and no MRSA was detected. The most distinguished resis-
tance was to fusidic acid, noted in 14 isolates during pre
intervention compared to one isolate during post intervention.
This may reflect an outbreak of S. aureus fusidic acid resis-
tance among Swedish children with bullous impetigo during
the mid-1990s [25].
Conclusions
The strong recommendation to perform a blood culture prior
to intravenous antibiotics resulted in an increased detection of
Staphylococcus aureus bacteremia (SAB), especially in men.
Hence, the SAB patients detected through the quality im-
provement program seems to have comparable mortality as
the pre intervention patients. Specific spa types could not be
correlated to clinical manifestations or mortality.
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